Home Ministry may drop use of azithromycin in COVID-19 treatment


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Home Ministry may drop use of azithromycin in COVID-19 treatment
The ministry is probably going to make the new treatment protocol public soon

The Union Health Ministry is probably going to revise protocols for the utilization of azithromycin together with anti-malarial drug hydroxychloroquine (HCQ) for the treatment of patients with the severe novel Coronavirus admitted in hospitals.
Reportedly, the matter has confirmed that the fresh treatment protocol, already getting used in AIIMS Delhi, doesn't mention the utilization of azithromycin as an administered drug alongside HCQ. The combination was earlier recommended by the ICMR. The ministry is probably going to make the new treatment protocol public soon.


"Use of azithromycin with hydroxychloroquine should be avoided as both prolong the interval between two waves in ECG also referred to as QTc prolongation. It causes heart problems. One can substitute doxycycline or amoxycyclin+ clavulanic acid as they're not known to cause this heart-related toxicity," a top ICMR official was quoted as saying.


Dr. Naveet Wig, Head of Department of drugs, AIIMS, and a member of the national task force on clinical research said was quoted saying, "For moderate to severe patients, the foremost important aspect is oxygenation. Anti-virals aren't being seen as effective within the cure of coronavirus. The treatment has evolved over time. Initially, azithromycin and HCQ was being given. Over time, with studies, we saw azithromycin are often avoided."
However, Dr. Wig cautioned that "these combinations depend upon a case-to-case basis. Guidelines should only be used as a guide".


"Anti-virals only act early within the case, then there's a requirement for anti-inflammatories. However, most stress is given on oxygenation within the initial stages," he further pointed out. Initially, azithromycin was given to the patients sometimes as there might be an opportunity of the patient developing a bacterial infection after testing positive for Covid-19.


Azithromycin is an antibiotic that stops the expansion of bacteria. It is primarily prescribed to treat various sorts of bacterial infections, including pneumonia, some sexually-transmitted diseases, bronchitis, and certain infections of the ear, throat, lungs, and sinuses. Azithromycin is usually prescribed to treat pertussis. The US National Library of drugs had said that this drug doesn't work for viral infections like cold or flu.
Some people are allergic to azithromycin and this drug is usually not given to those with liver conditions like jaundice.
Various studies are done thus far to check the effectiveness of azithromycin together with HCQ for the treatment of COVID-19 patients. In March, a study wiped out France suggested that azithromycin supplemented the consequences of HCQ in reducing viral load in Covid-19 patients.
However, another French study and a study wiped out the US said that the mixture of the 2 drugs was ineffective. The US study remains within the preprint phase and is yet to be peer-reviewed.

Tags : #Coronavirus #Azithromycin #Drug #COVID19 #HomeMinistry

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Rare Chest Wall Reconstruction at SRM Global Hospital Saves Critically Injured Road Accident VictimJuly 30, 2026
52-Year-Old Male with just 10% Heart Function successfully revived at Fortis Greater Noida via High-Risk Emergency AngioplastyJuly 30, 2026
Yashoda Hospitals Hitec City Achieves Landmark Milestone of 400+ Renal Transplants in less than 4 YearsJuly 30, 2026
Prostate Health Awareness: What Every Indian Man Must Know About Early Detection and PreventionJuly 30, 2026
Why Young Indians Are Facing Heart Problems: Causes, Warning Signs, and What to DoJuly 30, 2026
FemCare brand Healthfab acquires 2 acres land in Andhra Pradhesh to launch 2nd manufacturing facility for period care range of products; to invest Rs 15 crore July 29, 2026
Geriatric Wellness: New Technologies for Aging in Place GracefullyJuly 29, 2026
Digital Eye Strain 2.0: Protecting Vision in the Era of Spatial ComputingJuly 29, 2026
Endometriosis Awareness in India: Understanding the Condition That Affects Millions of Women in SilenceJuly 29, 2026
Prediabetes: Understanding the Critical Warning Stage Before DiabetesJuly 29, 2026
The Role of Microbiome in Pediatric Health: A New Era of Child WellnessJuly 28, 2026
The Rise of Bio-Individualized Diets: Tailoring Nutrition to Your DNAJuly 28, 2026
Immuneel Therapeutics and THSTI Announce Strategic Partnership to Advance CAR-T Cell Therapy and Lentiviral Vector Manufacturing July 28, 2026
Differential Diagnosis of Acute Abdomen: Differentiating Surgical Emergencies from Gastrointestinal MimicsJuly 28, 2026
Management of Rheumatic Heart Disease in Developing Nations: Secondary Prophylaxis and Valve InterventionsJuly 28, 2026
Hormonal Imbalance in Women: Understanding the Causes, Recognising the Symptoms, and Finding the Right TreatmentJuly 28, 2026
Why Regular Health Screening Matters: A Complete Guide for IndiansJuly 28, 2026
Galderma introduces Sculptra® in India, ushering in a new era of regenerative aestheticsJuly 27, 2026
Artificial Intelligence in Diagnostic Imaging: Enhancing Radiologist Precision and Reducing Human ErrorJuly 27, 2026
Transitioning from Acute Care to Urgent Care Centers: Optimizing Healthcare Facility InfrastructureJuly 27, 2026